Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

• Mark J. Selby,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• John J. Engelhardt,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Robert J. Johnston,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Li-Sheng Lu,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Minhua Han,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Kent Thudium,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Dapeng Yao,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Michael Quigley,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Jose Valle,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Changyu Wang,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Bing Chen,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Pina M. Cardarelli,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Diann Blanset,

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯
• Alan J. Korman

  * E-mail: alan.korman@bms.com

  Affiliation Bristol-Myers Squibb, Redwood City, CA, United States of America

  ⨯